← Leaderboards
Lisa Giulino Roth
Weill Medical Coll Of Cornell Univ
$4,411,176
Attributed
$6,642,059
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,642,059 · 3
By mechanism
U01$3,346,324 · 1
R37$2,611,281 · 1
K08$684,454 · 1
Top collaborators
- Ethel Cesarman4 shared
- Benjamin Elison Gewurz4 shared
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Ethel Cesarman$22,572,616
- Jez Lim Marston$161,206
- Steven Zvi Josefowicz$9,023,527
Others in their field
Other Emerging Leaders on “Lymphoma”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$22,138,591
- Leonard Freedman · Leidos Biomedical Research, Inc.$10,332,151
- Kathleen Nicol · Research Inst Nationwide Children'S Hosp$7,187,946
- Javeed Iqbal · University Of Nebraska Medical Center$5,566,166
- John Karijolich · Vanderbilt University Medical Center$5,446,739
Research focus
LymphomaEpstein-Barr Virus LatencyViralVirus LatencyTumorBurkitt LymphomaEpigenetic ProcessMediatingOncogenicViral ProteinsS LymphomaHuman Herpesvirus 4Large Cell Diffuse Non-Hodgkin&AposFutureCellsImmuneEpstein-Barr Virus-Related LymphomaImmunologicsImmunocompetentB-LymphocytesLeadViral GenomeProgramsUntranslated Rna
Grant awards (12)
B cell determinants of EBV latency$827,246
U01 · FY2025 · CA
Targeting Latency Switch in EBV+ Lymphomas$661,584
R37 · FY2025 · CA · contact PI
B cell determinants of EBV latency$827,278
U01 · FY2024 · CA
Targeting Latency Switch in EBV+ Lymphomas$628,505
R37 · FY2024 · CA · contact PI
B cell determinants of EBV latency$827,799
U01 · FY2023 · CA
Targeting Latency Switch in EBV+ Lymphomas$648,353
R37 · FY2023 · CA · contact PI
B cell determinants of EBV latency$864,001
U01 · FY2022 · CA
Targeting Latency Switch in EBV+ Lymphomas$672,839
R37 · FY2022 · CA · contact PI
Rational Translation of EZH2 Targeted Therapy in Germinal Center B-cell Lymphoma$171,180
K08 · FY2020 · CA · contact PI
Rational Translation of EZH2 Targeted Therapy in Germinal Center B-cell Lymphoma$171,180
K08 · FY2019 · CA · contact PI
Rational Translation of EZH2 Targeted Therapy in Germinal Center B-cell Lymphoma$170,914
K08 · FY2018 · CA · contact PI
Rational Translation of EZH2 Targeted Therapy in Germinal Center B-cell Lymphoma$171,180
K08 · FY2017 · CA · contact PI